Bronchopulmonary Dysplasia – Global Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Bronchopulmonary
Dysplasia – Pipeline Review, H1 2019” drug pipelines has been
added to ResearchAndMarkets.com’s offering.

Bronchopulmonary Dysplasia – Pipeline Review, H1 2019
provides comprehensive information on the therapeutics under development
for Bronchopulmonary Dysplasia (Respiratory), complete with analysis by
stage of development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The guide covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases.

The Bronchopulmonary Dysplasia (Respiratory) pipeline guide also reviews
of key players involved in therapeutic development for Bronchopulmonary
Dysplasia and features dormant and discontinued projects. The guide
covers therapeutics under Development by
Companies/Universities/Institutes, the molecules developed by Companies
in Filing rejected/Withdrawn, Phase II, Phase I, IND/CTA Filed,
Preclinical and Discovery stages are 1, 3, 1, 1, 10 and 2 respectively.
Similarly, the Universities portfolio in Preclinical stages comprises 1
molecules, respectively.

Scope

• The pipeline guide provides a snapshot of the global therapeutic
  landscape of Bronchopulmonary Dysplasia (Respiratory).
• The pipeline guide reviews pipeline therapeutics for Bronchopulmonary
  Dysplasia (Respiratory) by companies and universities/research
  institutes based on information derived from company and
  industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of
  development ranging from pre-registration till discovery and
  undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline
  products which comprise, product description, descriptive licensing
  and collaboration details, R&D brief, MoA & other developmental
  activities.
• The pipeline guide reviews key companies involved in Bronchopulmonary
  Dysplasia (Respiratory) therapeutics and enlists all their major and
  minor projects.
• The pipeline guide evaluates Bronchopulmonary Dysplasia (Respiratory)
  therapeutics based on mechanism of action (MoA), drug target, route of
  administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued
  pipeline projects.
• The pipeline guide reviews latest news related to pipeline
  therapeutics for Bronchopulmonary Dysplasia (Respiratory).

Reasons to Buy

• Procure strategically important competitor information, analysis, and
  insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio
  and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under
  development for Bronchopulmonary Dysplasia (Respiratory).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of
  leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players
  and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding
  Bronchopulmonary Dysplasia (Respiratory) pipeline depth and focus of
  Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by
  identifying prospective partners with the most attractive projects to
  enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects
  and understand from the know-how what drove them from pipeline.

Companies Mentioned

• Chiesi Farmaceutici SpA
• Ethypharm SA
• Insmed Inc
• MediPost Co Ltd
• Meridigen Biotech Co Ltd
• Radikal Therapeutics Inc
• Syntrix Biosystems Inc
• Takeda Pharmaceutical Co Ltd
• The Cell-Factory BVBA
• Therabron Therapeutics Inc
• United Therapeutics Corp

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/42szui

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Respiratory
Drugs